Loading
Fibromyalgia and Chronic Fatigue Syndrome Research / Genetic Neurodegenerative Diseases · Journal article
Journal of Translational Medicine · August 28, 2026
A consensus or society position rather than new primary data.
This is a broad narrative review of ME/CFS epidemiology, pathophysiology, and therapeutic evidence, synthesising current understanding and highlighting diagnostic, research, and treatment gaps. It documents formal withdrawal of Graded Exercise Therapy due to evidence of harm and identifies emerging pathophysiological mechanisms (mitochondrial dysfunction, immune dysregulation, neuroinflammation, microbiome alterations) and new diagnostic/therapeutic approaches under study, but does not present original trial data or quantify treatment efficacy.
Narrative review. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); literature on epidemiology, diagnosis, pathophysiology, and therapeutic approaches..
Formal withdrawal of Graded Exercise Therapy from treatment guidelines due to evidence of harm Post Exertional Malaise (PEM) identified as cardinal symptom of ME/CFS Emerging pathophysiological evidence implicates mitochondrial dysfunction, immune dysregulation, autonomic imbalance, neuroinflammation, and gut microbiome alterations
Formal withdrawal of Graded Exercise Therapy from treatment guidelines due to evidence of harm
Clinicians should be aware that Graded Exercise Therapy is no longer recommended due to documented harm. The review emphasises PEM as a cardinal diagnostic feature and notes that ME/CFS requires formal recognition to avoid patient marginalisation; however, definitive biomarkers and disease-modifying treatments remain under development.
A comprehensive narrative review synthesising epidemiology, pathophysiology, and therapeutic evidence for ME/CFS, offering clinical and research direction rather than reporting original data or a single definitive trial.
As stated by the source record.
Clinicians should be aware that Graded Exercise Therapy is no longer recommended due to documented harm. The review emphasises PEM as a cardinal diagnostic feature and notes that ME/CFS requires formal recognition to avoid patient marginalisation; however, definitive biomarkers and disease-modifying treatments remain under development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, debilitating disease that is unexplained and is characterised by persistent unexplained fatigue, Post Exertional Malaise (PEM), cognitive impairment, unrefreshing sleep and multisystem impairment. Despite the high burden of symptoms and the worldwide prevalence, ME/CFS has been poorly understood, underdiagnosed and underfunded. This large-scale review summarises the available evidence regarding the epidemiology, diagnostic progress, main clinical characteristics, pathophysiological theories and therapeutic approaches for ME/CFS. Despite problems with diagnostic consistency, the lack of validated biomarkers, and historical linkage to psychiatric illness, the recognition of this condition has been delayed and has led to patient marginalisation. The review highlights PEM as a cardinal symptom and reviews the weaknesses in earlier diagnostic criteria, as well as current changes in treatment guidelines, including the formal withdrawal of Graded Exercise Therapy, which has evidence of harm. New pathophysiological evidence suggests mitochondrial dysfunction, immune dysregulation, autonomic imbalance, neuroinflammation, and alterations in gut microbiome. New diagnostic and therapeutic strategies, such as metabolomic and electrophysiological assays, mTOR inhibitors, and decentralised clinical trial designs, are being studied. This intersection with Long COVID offers a chance to rapidly advance studies of post-infectious chronic diseases. The paper also argues for stringent subtyping, uniform data collection, and ongoing patient participation in research as strategies to surmount challenges of heterogeneity. Finally, it underscores the critical need for fair funding of research, so biomarker discovery and development of disease-modifying treatments can be achieved. The care of people with ME/CFS is not only a clinical obligation, but also a public health one.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.